FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology and biotechnology. What is presented is a nucleic acid coding a anti-human CD3 and CEA bi-specific one-chain antibody. Domain-binding CEA contains three CDRs of a light chain and three CDRs of a heavy chain, wherein CDR-H3 originates from anti-murine A5B7 monoclonal antibody. There is described: an expression vector, and a NC-based host cell, as well as a method for producing the bi-specific one-chain antibody with using the cell.
EFFECT: using the invention provides producing the antibody, which is stable to human soluble CEA that can find application in a therapy of epithelial tumours in the patients with high-CEA plasma.
14 cl, 27 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUBLE CD3 STABLE PHARMACEUTICAL COMPOSITIONS | 2006 |
|
RU2426743C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
| BISPECIFIC SINGLE-CHAIN ANTIBODY TO PSMAxCD3 WITH INTERSPECIES SPECIFICITY | 2011 |
|
RU2617942C2 |
| PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 | 2019 |
|
RU2798246C2 |
| CD3-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND THEIR APPLICATIONS | 2020 |
|
RU2808138C1 |
| BISPECIFIC BINDING AGENTS WITH INTERSPECIFIC SPECIFICITY | 2008 |
|
RU2535992C2 |
| CD3-EPSILON-BINDING DOMAIN HAVING INTERSPECIES SPECIFICITY | 2008 |
|
RU2561457C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
